beta-alanine has been researched along with Ischemic Attack, Transient in 16 studies
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events." | 8.90 | Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014) |
| "New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 8.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
| "This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin." | 7.80 | Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed." | 7.78 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 7.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| "Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events." | 4.90 | Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014) |
| "New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 4.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
| "This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin." | 3.80 | Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed." | 3.78 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 3.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, C | 1 |
| Zhu, L | 1 |
| Wu, J | 1 |
| Fang, S | 1 |
| Marrone, LC | 2 |
| Marrone, AC | 2 |
| Diener, HC | 1 |
| Weber, R | 1 |
| Sardar, P | 1 |
| Nairooz, R | 1 |
| Chatterjee, S | 1 |
| Wetterslev, J | 1 |
| Ghosh, J | 1 |
| Aronow, WS | 1 |
| Bin Abdulhak, AA | 1 |
| Khan, AR | 1 |
| Wimmer, AP | 1 |
| Larsen, TB | 1 |
| Rasmussen, LH | 1 |
| Gorst-Rasmussen, A | 1 |
| Skjøth, F | 1 |
| Lane, DA | 1 |
| Lip, GY | 1 |
| Calkins, H | 1 |
| Gerstenfeld, EP | 1 |
| Schilling, R | 1 |
| Verma, A | 1 |
| Willems, S | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Cantürk, E | 1 |
| Karaca, O | 1 |
| Omaygenç, O | 1 |
| Kızılırmak, F | 1 |
| Güler, E | 1 |
| Eikelboom, JW | 1 |
| Bosch, J | 1 |
| Freeman, JV | 1 |
| Zhu, RP | 1 |
| Owens, DK | 1 |
| Garber, AM | 1 |
| Hutton, DW | 1 |
| Go, AS | 1 |
| Wang, PJ | 1 |
| Turakhia, MP | 1 |
| Kamel, H | 1 |
| Johnston, SC | 1 |
| Easton, JD | 1 |
| Kim, AS | 1 |
| Mantha, S | 1 |
| Ansell, J | 1 |
| Spyropoulos, AC | 1 |
| Douketis, JD | 1 |
| Gerotziafas, G | 1 |
| Kaatz, S | 1 |
| Ortel, TL | 1 |
| Schulman, S | 1 |
| Aalbers, J | 1 |
| Hardy, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for beta-alanine and Ischemic Attack, Transient
| Article | Year |
|---|---|
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Hum | 2013 |
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr | 2014 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tri | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Pr | 2012 |
12 other studies available for beta-alanine and Ischemic Attack, Transient
| Article | Year |
|---|---|
What if a patient with atrial fibrillation and anticoagulant treatment is suffering from acute ischemia stroke?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Ischemic Attack, Transient; Male; Stroke; Thro | 2013 |
Acute ischemic stroke and new anticoagulants -- how to act in the acute phase of stroke?.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Ischemic Attack, Transient; Male; Stroke; Thro | 2013 |
Dabigatran in catheter ablation of atrial fibrillation: a call for a randomized control trial.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans | 2014 |
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
Case images: warfarin-induced skin necrosis: a 'novel' solution to an old problem.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Hu | 2014 |
Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ischemic Attack, T | 2015 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2011 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi | 2012 |
Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report.
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Fibrinolytic Agents; Humans; | 2012 |
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I | 2012 |